An $84,000 hepatitis drug is giving states and insurers a major headache
The new hepatitis C drug Sovaldi is being hailed as a potential breakthrough treatment for a disease that affects about 3.2 million Americans. It’s also vexing insurers, who worry about the drug’s $1,000-a-day-price tag. (The full 12-week course of treatment runs about $84,000).
Continue Reading http://www.washingtonpost.com
Join the Discussion